Global Interleukin Inhibitors Market 2024 , Forecast To 2033
7 Mar, 2024
The interleukin inhibitors market has experienced rapid growth recently, with its size expanding from $42.93 billion in 2023 to $49.84 billion in 2024, marking a compound annual growth rate (CAGR) of 16.1%. This growth can be attributed to factors such as the rising prevalence of autoimmune diseases, increased awareness of interleukin inhibitors, and the demand for personalized medicine. Looking ahead, the market is expected to continue its robust expansion, reaching $96.66 billion in 2028 at a CAGR of 18.0%. This growth will likely be fueled by emerging therapeutic indications, a global aging population, and increased investment in research and development. Major trends in this period are anticipated to include the development of oral interleukin inhibitors, next-generation therapies, and pediatric indications, among others.
Global Interleukin Inhibitors Market Key Driver
An increase in investigational drugs for inflammatory diseases will drive the interleukin inhibitors market (2). With 48 molecules under investigation, including 20 in Phase III clinical trials for diseases like psoriasis, arthritis, and inflammatory bowel disease, the market for interleukin inhibitors is expected to grow significantly upon approval of these pipeline drugs.
Get A Free Sample Of The Global Interleukin Inhibitors Market ReportGlobal Interleukin Inhibitors Market Segments
The interleukin inhibitors market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Other Types
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the interleukin inhibitors market in 2023. The regions covered in the interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Interleukin Inhibitors Industry Players
Sanofi S.A.; GlaxoSmithKline plc; Novartis International AG; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; AstraZeneca plc; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Bausch Health Companies Inc.; AbbVie Inc.; Sun Pharmaceutical Industries Limited; Boehringer Ingelheim International GmbH; Janssen Biotech Inc.; Ortho Dermatologics; Amgen Inc.; Celgene Corporation; Bristol-Myers Squibb Company; Pfizer Inc.; Merck & Co. Inc.; Takeda Pharmaceutical Company Limited; Biogen Inc.; Vertex Pharmaceuticals Incorporated; Incyte Corporation; Seattle Genetics Inc.; Genentech Inc.; Karyopharm Therapeutics Inc.; Kyowa Kirin Co Ltd.; Astellas Pharma Inc.; Ipsen Biopharmaceuticals Inc.
Get The Full Global Interleukin Inhibitors Market Report
Interleukin Inhibitors Market Overview
Interleukin inhibitors refer to a substance used to suppress the immune system that prevents interleukins from working. Interleukins are a class of cytokines produced by white blood cells in response to infection (lymphocytes, monocytes, and macrophages). They are crucial to the control of the immune system.